Viswam S Nair

Dr. Viswam S Nair


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JCJacob J. Chabon
Jacob J. Chabon
EHEmily G. Hamilton
Emily G. Hamilton
DKDavid M. Kurtz
David M. Kurtz
MEMohammad S. Esfahani
Mohammad S. Esfahani
EMEverett J. Moding
Everett J. Moding
MDMaximilian Diehn
Maximilian Diehn

12 December 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SPSeung-min Park
Seung-min Park
DWDawson J. Wong
Dawson J. Wong
COChinchun Ooi
Chinchun Ooi
DKDavid M. Kurtz
David M. Kurtz
OVOphir Vermesh
Ophir Vermesh
SGSanjiv S. Gambhir
Sanjiv S. Gambhir
Significance: There exists an urgent need for minimally invasive molecular analysis tools for cancer assessment and management, particularly in advanced-stage lung cancer, when tissue procurement is challenging and gene mutation profiling is crucial to identify molecularly targeted agents for treatment. High-throughput compartmentalization and multigene profiling of individual circulating tumor cells (CTCs) from whole-blood samples using modular gene panels may facilitate highly sensitive, yet minimally invasive characterization of lung cancer for therapy prediction and monitoring. We envision this nanoplatform as a compelling research tool to investigate the dynamics of cancer disease processes, as well as a viable clinical platform for minimally invasive yet comprehensive cancer assessment.

1 May 2010 in Chest
Verified
Journal Article
Closed access
VNViswam S Nair
Viswam S Nair
PBPaul G. Barnett
Paul G. Barnett
LALakshmi Ananth
Lakshmi Ananth
MGMichael K. Gould
Michael K. Gould

1 June 2017 in Preventive Medicine Reports
Verified
Journal Article
Open access
DDDuy K. Duong
Duy K. Duong
SSSalma Shariff-Marco
Salma Shariff-Marco
ICIona Cheng
Iona Cheng
HNHarris Naemi
Harris Naemi
LMLisa M. Moy
Lisa M. Moy
VNViswam S Nair
Viswam S Nair
Low dose CT (LDCT) for lung cancer screening is an evidence-based, guideline recommended, and Medicare approved test but uptake requires further study. We therefore conducted patient and provider surveys to elucidate factors associated with utilization. Patients referred for LDCT at an academic medical center were questioned about their attitudes, knowledge, and beliefs on lung cancer screening. Adherent patients were defined as those who met screening eligibility criteria and completed a LDCT. Referring primary care providers within this same medical system were surveyed in parallel about their practice patterns, attitudes, knowledge and beliefs about screening. Eighty patients responded (36%), 48 of whom were adherent. Among responders, non-Hispanic patients (p = 0.04) were more adherent. Adherent respondents believed that CT technology is accurate and early detection is useful, and they trusted their providers. A majority of non-adherent patients (79%) self-reported an intention to obtain a LDCT in the future. Of 36 of 87 (41%) responding providers, only 31% knew the correct lung cancer screening eligibility criteria, which led to a 37% inappropriate referral rate from 2013 to 2015. Yet, 75% had initiated lung cancer screening discussions, 64% thought screening was at least moderately effective, and 82% were interested in learning more of the 33 providers responding to these questions. Overall, patients were motivated and providers engaged to screen for lung cancer by LDCT. Non-adherent patient "procrastinators" were motivated to undergo screening in the future. Additional follow through on non-adherence may enhance screening uptake, and raising awareness for screening eligibility through provider education may reduce inappropriate referrals.

16 April 2025 in Nature
Verified
Journal Article
Closed access
PDF file
MNMonica C. Nesselbush
Monica C. Nesselbush
BLBogdan A. Luca
Bogdan A. Luca
YJYoung-Jun Jeon
Young-Jun Jeon
IJIsabel Jabara
Isabel Jabara
CMCatherine B. Meador
Catherine B. Meador
MDMaximilian Diehn
Maximilian Diehn

1 February 2014 in Lung Cancer
Verified
Journal Article
Closed access
VNViswam S Nair
Viswam S Nair
OGOlivier Gevaert
Olivier Gevaert
GDGuido Alejandro Davidzon
Guido Alejandro Davidzon
SPSylvia K. Plevritis
Sylvia K. Plevritis
RWRobert West
Robert West